
ITRM
Iterum Therapeutics PLC
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.8701
Open
0.8315
VWAP
0.84
Vol
456.79K
Mkt Cap
33.00M
Low
0.8211
Amount
384.15K
EV/EBITDA(TTM)
--
Total Shares
16.55M
EV
52.57M
EV/OCF(TTM)
--
P/S(TTM)
--
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Show More
2 Analyst Rating

748.48% Upside
Wall Street analysts forecast ITRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITRM is 7.00 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy

748.48% Upside
Current: 0.825

Low
5.00
Averages
7.00
High
9.00

748.48% Upside
Current: 0.825

Low
5.00
Averages
7.00
High
9.00
H.C. Wainwright
H.C. Wainwright
initiated
$9
2025-05-08
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$9
2025-05-08
initiated
Reason
H.C. Wainwright assumed coverage of Iterum Therapeutics with a Buy rating and $9 price target. Iterum is a pre-commercial stage company with an FDA approved product, the analyst tells investors in a research note. The firm says the company has the potential to deliver in urinary tract infections and infectious disease.
HC Wainwright & Co.
Ed Arce
Strong Buy
Reiterates
$5
2024-09-10
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$5
2024-09-10
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Ed Arce
Strong Buy
Maintains
$6 → $5
2024-08-15
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$6 → $5
2024-08-15
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Iterum Therapeutics PLC (ITRM.O) is -2.84, compared to its 5-year average forward P/E of -2.01. For a more detailed relative valuation and DCF analysis to assess Iterum Therapeutics PLC 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-2.01
Current PE
-2.84
Overvalued PE
0.42
Undervalued PE
-4.44
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-0.91
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.16
Undervalued EV/EBITDA
-2.98
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
393.08
Current PS
4.25
Overvalued PS
2102.38
Undervalued PS
-1316.23
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
-39.80%
-3.71M
Operating Profit
FY2025Q1
YoY :
-31.12%
-4.89M
Net Income after Tax
FY2025Q1
YoY :
-69.57%
-0.14
EPS - Diluted
FY2025Q1
YoY :
-76.60%
-3.06M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ITRM News & Events
Events Timeline
2025-06-30 (ET)
2025-06-30
07:03:07
Iterum Therapeutics appoints Coyne as CCO

2025-06-25 (ET)
2025-06-25
07:10:36
Iterum Therapeutics announces publication of REASSURE trial in NEJM Evidence

2025-06-11 (ET)
2025-06-11
07:12:26
Iterum Therapeutics announces partnership for commercialization services

Sign Up For More Events
Sign Up For More Events
News
5.0
06-30NewsfilterIterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth
9.0
06-25NewsfilterIterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence
7.5
06-11NewsfilterIterum Therapeutics Announces Partnership for Commercialization Services
Sign Up For More News
People Also Watch

ESHA
ESH Acquisition Corp
11.110
USD
-0.99%

VTVT
vTv Therapeutics Inc
15.570
USD
-1.33%

ARBK
Argo Blockchain PLC
0.381
USD
0.00%

PXS
Pyxis Tankers Inc
3.050
USD
+3.04%

ELEV
Elevation Oncology Inc
0.377
USD
-2.19%

RAPT
RAPT Therapeutics Inc
12.650
USD
-9.25%

DMYY
DMY Squared Technology Group Inc
12.880
USD
+3.70%

LGCL
Lucas GC Ltd
1.005
USD
-0.50%

BCG
Binah Capital Group Inc
2.360
USD
-5.60%

BRNS
Barinthus Biotherapeutics PLC
1.745
USD
-8.64%
FAQ

What is Iterum Therapeutics PLC (ITRM) stock price today?
The current price of ITRM is 0.825 USD — it has decreased -0.6 % in the last trading day.

What is Iterum Therapeutics PLC (ITRM)'s business?

What is the price predicton of ITRM Stock?

What is Iterum Therapeutics PLC (ITRM)'s revenue for the last quarter?

What is Iterum Therapeutics PLC (ITRM)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Iterum Therapeutics PLC (ITRM)'s fundamentals?

How many employees does Iterum Therapeutics PLC (ITRM). have?
